利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

104 条记录 (耗时 0.068 秒)

    Methods Of Generating High-Production Of Antibodies From Hybridomas Created By In Vitro Immunization
    67.
    发明申请
    Methods Of Generating High-Production Of Antibodies From Hybridomas Created By In Vitro Immunization 有权
    通过体外免疫产生的杂交瘤产生高产抗体的方法

    公开(公告)号：US20100311169A1

    公开(公告)日：2010-12-09

    申请号：US12786530

    申请日：2010-05-25

    申请人： Luigi Grasso ,  Shaohong Liang ,  Nicholas C. Nicolaides ,  Philip M. Sass

    发明人： Luigi Grasso ,  Shaohong Liang ,  Nicholas C. Nicolaides ,  Philip M. Sass

    IPC分类号： C12N15/06 ,  C12N15/01

    CPC分类号： C12N15/01 ,  C07K16/00 ,  C07K16/1282 ,  C07K16/243 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/73 ,  C12N15/1024

    摘要： The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.

    摘要翻译： 本发明提供了通过将骨髓瘤细胞与体外免疫的供体细胞融合而产生的杂交瘤细胞产生高亲和力抗体的高滴度的方法。 具有来自产生高亲和力抗体的杂交瘤的克隆抗体基因的杂交瘤细胞或哺乳动物表达细胞可能是错配修复缺陷，这是由于通过表达不匹配修复基因的显性负等位基因的内源性错配修复亚基的缺陷而允许杂交瘤 细胞可变性，可以通过化学方式使其变得过度，或者可能是天然错配修复缺陷。 可以通过本发明的方法制备产生抗体的高亲和力抗体和高滴度产生细胞。

    Anti-Mesothelin Antibodies
    68.
    发明申请
    Anti-Mesothelin Antibodies 有权
    抗间皮素抗体

    公开(公告)号：US20100028336A1

    公开(公告)日：2010-02-04

    申请号：US12545369

    申请日：2009-08-21

    申请人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    发明人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    IPC分类号： A61K39/395 ,  C07H21/04 ,  A61P35/00 ,  C12N15/74 ,  C12N5/16

    CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77

    摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

    摘要翻译： 本发明涉及单克隆和多克隆抗体的使用，其特异性结合并被间皮素阳性细胞内化，并且还诱导免疫效应子活性如抗体依赖性细胞毒性。 该抗体可用于特异性递送表达间皮素的药物学药剂，以及引发免疫效应物特异性对肿瘤细胞和前体的活性。 本发明还涉及表达单克隆抗体，多克隆抗体，抗体衍生物如人，人源化和嵌合单克隆抗体的细胞，抗体片段，表达单克隆抗体的哺乳动物细胞，衍生物和片段，以及使用 抗体，衍生物和片段。

    Nucleic acid encoding an interleukin-9 receptor variant
    70.
    发明授权
    Nucleic acid encoding an interleukin-9 receptor variant 失效
    编码白细胞介素-9受体变体的核酸

    公开(公告)号：US07384767B2

    公开(公告)日：2008-06-10

    申请号：US11700260

    申请日：2007-01-31

    申请人： Roy Clifford Levitt ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Kenneth J. Holroyd

    发明人： Roy Clifford Levitt ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Kenneth J. Holroyd

    IPC分类号： C12N5/10 ,  C12N15/12 ,  C12N15/63

    CPC分类号： C12Q1/6883 ,  A61K38/00 ,  C07K14/7155 ,  C12Q2600/156

    摘要： This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.

    摘要翻译： 本发明涉及用于发现基于哮喘相关因子2变体的特应性哮喘和相关病症的新治疗剂的诊断，治疗和方法。本发明的一个实施方案是AAF2的变体，其中密码子173缺失导致 来自成熟蛋白质前体的谷氨酰胺173。 该单个氨基酸缺失导致非功能性AAF2蛋白，因此该表型的存在应该与较少的特应性哮喘证据相关。 相应地，对哮喘，特应性表型的敏感性的缺乏的特征在于密码子171处的谷氨酰胺的丧失。本发明包括作为野生型序列的变体的分离的DNA分子以及由这样的DNA编码的蛋白质 DNA分子和表达蛋白在特应性哮喘的诊断和治疗中的应用。